Klinman D M, Takeno M, Ichino M, Gu M, Yamshchikov G, Mor G, Conover J
Section of Retroviral Immunology, Food and Drug Administration, Bethesda, MD 20892, USA.
Springer Semin Immunopathol. 1997;19(2):245-56. doi: 10.1007/BF00870272.
DNA technology has been harnessed to produce a variety of plasmid-based vaccines designed to prevent viral, bacterial and parasitic infections. The rapid adoption and implementation of this novel vaccine strategy carries with it important safety and efficacy concerns. This review will focus on whether DNA vaccines (1) are likely to induce systemic or organ-specific autoimmune disease, (2) have the potential to induce tolerance rather than immunity, and (3) are as effective in individuals with depressed immune function as they are in healthy adults.
DNA技术已被用于生产多种基于质粒的疫苗,旨在预防病毒、细菌和寄生虫感染。这种新型疫苗策略的迅速采用和实施带来了重要的安全性和有效性问题。本综述将聚焦于DNA疫苗是否(1)可能诱发全身性或器官特异性自身免疫性疾病,(2)有诱导耐受而非免疫的潜力,以及(3)在免疫功能低下的个体中是否与在健康成年人中一样有效。